Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q4 - Annual Results

Exhibit 99.1 Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise About Artiva Biotherapeutics Artiva is a clinical-sta ...